Haemonetics ( (HAE) ) has released its Q3 earnings. Here is a breakdown of the information Haemonetics presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Haemonetics Corporation is a global healthcare company specializing in innovative medical products and solutions, particularly in the fields of blood and plasma component collection, surgical suites, and hospital transfusion services.
The company has reported its financial results for the third quarter and year-to-date of fiscal 2025, showing a positive trend despite external market challenges. Key highlights include a significant increase in operating margins and revenue growth in the Hospital segment, which helped offset declines in other areas.
Haemonetics’ third-quarter revenue rose to $349 million, marking a 3.7% increase from the previous year, driven by a remarkable 23.9% rise in the Hospital unit. However, the Plasma and Blood Center units experienced declines of 9.1% and 2.8%, respectively. The company’s adjusted earnings per diluted share grew by 14.4%, reaching $1.19, indicating strong profitability enhancements. Operating income also grew significantly, with a reported $59 million, showcasing a 28.4% increase year-over-year.
The company has also updated its fiscal 2025 guidance, projecting a cautious yet optimistic outlook. Despite revising its total revenue growth forecast downwards, Haemonetics expects to maintain a stable adjusted operating margin of around 24% and adjusted earnings per share between $4.50 and $4.70.
Going forward, Haemonetics remains confident in its strategic initiatives aimed at expanding its portfolio and driving long-term growth. The company’s leadership is focused on leveraging its differentiated technologies to strengthen market share and improve patient care outcomes globally.
